BMS CV002-004: A Longitudinal Evaluation of Disease and Fibrosis Biomarkers in Different Groups of Heart Failure Patients to Enhance the Early Clinical Development of Compounds with Anti-fibrotic Activity in the Heart

Grants and Contracts Details

StatusFinished
Effective start/end date11/21/1611/28/18

Funding

  • Bristol Myers Squibb Company: $59,671.00